The therapeutic perspective of NAD + precursors in age-related diseases
AHK-Cu targets follicles at the cellular level
In animal research, significant reductions in body weight gain were observed over treatment periods of 14-19 days, with sustained effects during chronic administration
These adaptations may explain why metabolic benefits can continue to improve over weeks to months of consistent use, rather than plateauing immediately
Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels
These include sarcoidosis, high phosphate blood levels, high calcium blood levels, excessive vitamin D levels, arteriosclerosis with occlusion of the arteries, kidney stones, kidney disease with reduced kidney function, and allergies to vitamin D